Emavusertib in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematological Malignancies
Wednesday, June 8, 2022
12:00pm EDT
This website uses cookies to improve your browsing experience
and analyze site traffic. By using our site, you consent to our use of
cookies, in accordance with our privacy policies.
I Understand
